Find an expert
Our panel of editors are available for interview
Professor Ronald F. van Vollenhoven
Editor-in-Chief of Lupus Science & Medicine
Professor Ronald F. van Vollenhoven is a distinguished rheumatologist and immunologist, known for his significant contributions in the field. He currently holds the position of Chair of the Department of Rheumatology and Clinical Immunology at Amsterdam UMC and directs the Amsterdam Rheumatology Centre. With a background in immunology and extensive training in Internal Medicine and Rheumatology, he has dedicated his career to the development and evaluation of biological and immunomodulatory treatments for rheumatic diseases. Dr. Van Vollenhoven has played a pivotal role in establishing crucial registries, including the Stockholm registry for biological therapies (STURE database), and has been a principal investigator in numerous clinical trials.
Dr James Cave
Editor-in-Chief of the Drugs and Therapeutics Bulletin
Dr James Cave has been a GP for over 25 years. He currently works for Red Whale, providing courses for GP’s that take the latest research and demonstrate how it might be used in practice. James was awarded an OBE for services to medicine in 2009.
Karen L Furie, MD
Editor-in-Chief of the Journal of Neurology, Neurosurgery and Psychiatry
Karen Furie, MD, MPH is Neurologist-in-Chief, Rhode Island Hospital, the Miriam Hospital and Bradley Hospital Samuel I Kennison, MD and Bertha S Kennison Professor of Clinical Neuroscience Chair of Neurology, the Warren Alpert Medical School of Brown University. Clinical and translational stroke research has been a major focus of Karen’s career, and she has enjoyed success in developing collaborative multispecialty initiatives.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.
